Journal: bioRxiv
Article Title: Functional and structural characterization of a combination of pan-sarbecovirus antibodies with potent antiviral activity
doi: 10.1101/2025.03.30.646023
Figure Lengend Snippet: (A-C) Golden Syrian hamsters (6 per group) were prophylactically treated with isotype control (palivizumab [anti-RSV F mAb] variable regions expressed as human IgG1 with LS mutation), bebtelovimab, sotrovimab VH/VL - huIgG1-LS (sotrovimab variable regions expressed as human IgG1 with LS mutation), PRO-37587 and GB-0669 as single agents and in combination, at the indicated doses one day prior to challenge with SARS-CoV-2 Omicron BA.2 (2.8x10 3 TCID50/dose). Four days post-challenge the hamsters were euthanized, lungs were harvested, and the following parameters measured: (A) TCID50 per gram (g) of lung tissue (dotted line indicates lower limit of detection, 1,656 TCID50/g). (B, C) Copies of genomic RNA (B) and subgenomic RNA (C) per g of lung tissue (dotted line indicates lower limit of detection, 200 copies/g). (D-F) hACE2 AC70 mice (10 per group) were prophylactically treated with isotype control (palivizumab [anti-RSV F mAb] variable regions expressed as human IgG1 with LS mutation), pemivibart, PRO-37587 and GB-0669 as single agents and in combination, at the indicated doses one day prior to challenge with SARS-CoV-2 Omicron XBB.1.5. (D) Five mice per group were allowed to progress to study end date and percent survival for each group is reported up to day 14 post-challenge. (E, F) Five mice per group were euthanized on day 4 days post-challenge and lungs were harvested to quantify TCID50 and subgenomic RNA. (E) TCID50 per gram (g) of lung tissue (dotted line indicates lower limit of detection, 4,098 TCID50/g). (F) Copies of subgenomic RNA per g of lung tissue (dotted line indicates lower limit of detection, 200 copies/g). Results in A-C, E and F are reported as individual data points, with lines representing median values. * and ** respectively indicate p ≤ 0.05 and p ≤ 0.01 when comparing experimental groups to isotype group.
Article Snippet: CV3-25, , S2X259, the isotype control (palivizumab [anti-RSV F mAb] variable regions [ https://www.imgt.org/3Dstructure-DB/cgi/details.cgi?pdbcode=7753 ] expressed as human IgG1 with LS mutation), bebtelovimab ( https://www.imgt.org/3Dstructure-DB/cgi/details.cgi?pdbcode=12145 ), and sotrovimab VH/VL -huIgG1-LS (sotrovimab variable regions [ https://www.imgt.org/3Dstructure-DB/cgi/details.cgi?pdbcode=11766 ] expressed as human IgG1 with LS mutation) were produced at GenScript.
Techniques: Control, Mutagenesis
MedChemExpress is a verified supplier 
MedChemExpress manufactures this product 
![(A-C) Golden Syrian hamsters (6 per group) were prophylactically treated with isotype control (palivizumab [anti-RSV F mAb] variable regions expressed as human IgG1 with LS mutation), bebtelovimab, sotrovimab VH/VL - huIgG1-LS (sotrovimab variable regions expressed as human IgG1 with LS mutation), PRO-37587 and GB-0669 as single agents and in combination, at the indicated doses one day prior to challenge with SARS-CoV-2 Omicron BA.2 (2.8x10 3 TCID50/dose). Four days post-challenge the hamsters were euthanized, lungs were harvested, and the following parameters measured: (A) TCID50 per gram (g) of lung tissue (dotted line indicates lower limit of detection, 1,656 TCID50/g). (B, C) Copies of genomic RNA (B) and subgenomic RNA (C) per g of lung tissue (dotted line indicates lower limit of detection, 200 copies/g). (D-F) hACE2 AC70 mice (10 per group) were prophylactically treated with isotype control (palivizumab [anti-RSV F mAb] variable regions expressed as human IgG1 with LS mutation), pemivibart, PRO-37587 and GB-0669 as single agents and in combination, at the indicated doses one day prior to challenge with SARS-CoV-2 Omicron XBB.1.5. (D) Five mice per group were allowed to progress to study end date and percent survival for each group is reported up to day 14 post-challenge. (E, F) Five mice per group were euthanized on day 4 days post-challenge and lungs were harvested to quantify TCID50 and subgenomic RNA. (E) TCID50 per gram (g) of lung tissue (dotted line indicates lower limit of detection, 4,098 TCID50/g). (F) Copies of subgenomic RNA per g of lung tissue (dotted line indicates lower limit of detection, 200 copies/g). Results in A-C, E and F are reported as individual data points, with lines representing median values. * and ** respectively indicate p ≤ 0.05 and p ≤ 0.01 when comparing experimental groups to isotype group.](https://bio-rxiv-images-cdn.bioz.com/dois_ending_with_23/10__1101_slash_2025__03__30__646023/10__1101_slash_2025__03__30__646023___F7.large.jpg)